Citadel Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.8K | Sell |
148,900
-73,200
| -33% | -$29.1K | ﹤0.01% | 12521 |
|
|
2025
Q4 | $93.3K | Sell |
222,100
-10,400
| -4% | -$5.51K | ﹤0.01% | 11698 |
|
|
2025
Q3 | $157K | Sell |
232,500
-21,000
| -8% | -$11.3K | ﹤0.01% | 11505 |
|
|
2025
Q2 | $137K | Buy |
253,500
+68,800
| +37% | +$40.9K | ﹤0.01% | 11046 |
|
|
2025
Q1 | $121K | Buy |
184,700
+53,400
| +41% | +$56.5K | ﹤0.01% | 11197 |
|
|
2024
Q4 | $134K | Buy |
131,300
+80,900
| +161% | +$148K | ﹤0.01% | 11055 |
|
|
2024
Q3 | $43.7K | Buy |
50,400
+35,100
| +229% | +$25.7K | ﹤0.01% | 12057 |
|
|
2024
Q2 | $5.48K | Sell |
15,300
-4,100
| -21% | -$2.21K | ﹤0.01% | 13398 |
|
|
2024
Q1 | $13K | Sell |
19,400
-42,600
| -69% | -$30.9K | ﹤0.01% | 13322 |
|
|
2023
Q4 | $33.7K | Sell |
62,000
-2,500
| -4% | -$1.15K | ﹤0.01% | 12170 |
|
|
2023
Q3 | $38.7K | Buy |
64,500
+7,300
| +13% | +$7.82K | ﹤0.01% | 12038 |
|
|
2023
Q2 | $74.4K | Hold |
57,200
| – | – | ﹤0.01% | 11321 |
|
|
2023
Q1 | $101K | Sell |
57,200
-36,100
| -39% | -$103K | ﹤0.01% | 11253 |
|
|
2022
Q4 | $293K | Sell |
93,300
-15,000
| -14% | -$58.2K | ﹤0.01% | 9371 |
|
|
2022
Q3 | $531K | Buy |
108,300
+5,800
| +6% | +$29.8K | ﹤0.01% | 8329 |
|
|
2022
Q2 | $424K | Buy |
102,500
+11,000
| +12% | +$47.6K | ﹤0.01% | 9029 |
|
|
2022
Q1 | $532K | Buy |
91,500
+2,300
| +3% | +$13.7K | ﹤0.01% | 9241 |
|
|
2021
Q4 | $669K | Buy |
89,200
+19,600
| +28% | +$170K | ﹤0.01% | 8946 |
|
|
2021
Q3 | $627K | Sell |
69,600
-14,500
| -17% | -$143K | ﹤0.01% | 9321 |
|
|
2021
Q2 | $1.01M | Sell |
84,100
-1,000
| -1% | -$11.3K | ﹤0.01% | 8359 |
|
|
2021
Q1 | $1.07M | Sell |
85,100
-166,400
| -66% | -$2.24M | ﹤0.01% | 7958 |
|
|
2020
Q4 | $3.92M | Sell |
251,500
-117,900
| -32% | -$1.38M | ﹤0.01% | 4096 |
|
|
2020
Q3 | $3.49M | Sell |
369,400
-11,700
| -3% | -$127K | ﹤0.01% | 3716 |
|
|
2020
Q2 | $3.42M | Sell |
381,100
-28,700
| -7% | -$266K | ﹤0.01% | 3640 |
|
|
2020
Q1 | $2.61M | Buy |
409,800
+261,200
| +176% | +$1.94M | ﹤0.01% | 3694 |
|
|
2019
Q4 | $1.24M | Sell |
148,600
-40,000
| -21% | -$368K | ﹤0.01% | 5215 |
|
|
2019
Q3 | $1.71M | Sell |
188,600
-90,500
| -32% | -$1.02M | ﹤0.01% | 4744 |
|
|
2019
Q2 | $3.01M | Buy |
279,100
+12,900
| +5% | +$137K | ﹤0.01% | 3853 |
|
|
2019
Q1 | $2.54M | Sell |
266,200
-77,500
| -23% | -$792K | ﹤0.01% | 4061 |
|
|
2018
Q4 | $3.95M | Buy |
343,700
+57,900
| +20% | +$719K | ﹤0.01% | 3126 |
|
|
2018
Q3 | $4.84M | Buy |
285,800
+75,500
| +36% | +$1.15M | ﹤0.01% | 3049 |
|
|
2018
Q2 | $2.99M | Buy |
210,300
+89,200
| +74% | +$1.48M | ﹤0.01% | 3487 |
|
|
2018
Q1 | $2.3M | Buy |
121,100
+22,400
| +23% | +$479K | ﹤0.01% | 3513 |
|
|
2017
Q4 | $1.62M | Buy |
98,700
+10,700
| +12% | +$159K | ﹤0.01% | 3934 |
|
|
2017
Q3 | $1.32M | Buy |
88,000
+22,800
| +35% | +$252K | ﹤0.01% | 3934 |
|
|
2017
Q2 | $574K | Buy |
65,200
+51,000
| +359% | +$327K | ﹤0.01% | 4925 |
|
|
2017
Q1 | $74K | Sell |
14,200
-34,400
| -71% | -$138K | ﹤0.01% | 6953 |
|
|
2016
Q4 | $148K | Sell |
48,600
-10,000
| -17% | -$36.4K | ﹤0.01% | 6516 |
|
|
2016
Q3 | $271K | Sell |
58,600
-12,800
| -18% | -$65.1K | ﹤0.01% | 5838 |
|
|
2016
Q2 | $413K | Sell |
71,400
-13,000
| -15% | -$82.9K | ﹤0.01% | 4753 |
|
|
2016
Q1 | $511K | Buy |
84,400
+19,700
| +30% | +$118K | ﹤0.01% | 4377 |
|
|
2015
Q4 | $591K | Sell |
64,700
-14,300
| -18% | -$110K | ﹤0.01% | 4246 |
|
|
2015
Q3 | $446K | Buy |
79,000
+14,200
| +22% | +$117K | ﹤0.01% | 4966 |
|
|
2015
Q2 | $719K | Buy |
64,800
+4,000
| +7% | +$51.6K | ﹤0.01% | 4438 |
|
|
2015
Q1 | $953K | Buy |
60,800
+10,500
| +21% | +$162K | ﹤0.01% | 3987 |
|
|
2014
Q4 | $765K | Buy |
50,300
+100
| +0.2% | +$1.21K | ﹤0.01% | 4121 |
|
|
2014
Q3 | $541K | Buy |
50,200
+8,800
| +21% | +$115K | ﹤0.01% | 4518 |
|
|
2014
Q2 | $632K | Sell |
41,400
-9,800
| -19% | -$141K | ﹤0.01% | 4100 |
|
|
2014
Q1 | $926K | Buy |
51,200
+9,900
| +24% | +$191K | ﹤0.01% | 3517 |
|
|
2013
Q4 | $574K | Buy |
41,300
+1,700
| +4% | +$19.6K | ﹤0.01% | 3847 |
|
|
2013
Q3 | $415K | Sell |
39,600
-21,500
| -35% | -$214K | ﹤0.01% | 4009 |
|
|
2013
Q2 | $477K | Buy |
+61,100
| New | +$533K | ﹤0.01% | 3882 |
|
Other funds holding SGMO
AC
VCM
VFT
Citadel Advisors's SGMO Position: Q4 2025 in Review
Citadel Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 1,208,415 shares — an estimated $641K sold.
Citadel Advisors first reported a position in SGMO in Q2 2013 and held it in 48 quarters. The position peaked at $20.5M in Q2 2019. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.
- Citadel Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 1,208,415 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $641K.
- Citadel Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 48 quarters.
- Citadel Advisors's SANGAMO THERAPEUTICS INC position peaked at $20.5M in Q2 2019.
- 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.